CytomX Therapeutics (CTMX) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 81.3% versus a loss of 23.4%. Over five years, CTMX leads with a -50.4% price change compared with -56.4% for SLN. Silence Therapeutics Plc American Depository Share is the larger company by market cap ($591.7 million vs $538.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | SLN |
|---|---|---|
| Share price | $2.47 | $9.52 |
| Market cap | $538.21M | $591.71M |
| 1-day change | -3.14% | -3.05% |
| YTD return | -40.14% | +56.58% |
| 1-year return | -23.42% | +81.33% |
| 5-year return | -50.39% | -56.37% |
| EPS (TTM) | $-0.51 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.21 | $17.58 |
| 52-week low | $2.43 | $4.19 |
| Distance from 52-week high | -69.91% | -45.84% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +395.95% | +246.64% |
| Average volume | 3.38M | 1.12M |
| Shares outstanding | 217.90M | 62.15M |
| Employees | 69 | 88 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed CTMX by 104.8 percentage points over the past year.
- The two companies sit in different sectors: CytomX Therapeutics in Health Care and Silence Therapeutics Plc American Depository Share in Healthcare.
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Healthcare · Biotechnology · 88 employees
CTMX vs SLN FAQ
Which is bigger, CytomX Therapeutics or Silence Therapeutics Plc American Depository Share?
Silence Therapeutics Plc American Depository Share (SLN) is larger, with a market capitalization of $591.71M compared with $538.21M for CytomX Therapeutics (CTMX).
Which stock has performed better over the past year, CTMX or SLN?
SLN returned +81.33% over the past 12 months, compared with -23.42% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are CytomX Therapeutics and Silence Therapeutics Plc American Depository Share in the same industry?
No. CytomX Therapeutics is in the Health Care sector, while Silence Therapeutics Plc American Depository Share is in Healthcare.